Study S001003

A Randomized, Multicenter, Open-Label, Parallel-Group, 28 Days Phase IV Study Comparing The Postprandial Plasma Glucose Profile of Lixisenatide With That of Sitagliptin Add-On to Insulin Glargine in Type 2 Diabetes Mellitus

Included trial: extracted data ClinicalTrials.gov record

Registration

Registration: NCT02200991
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE4
Masking: NONE
Status: COMPLETED
Enrollment: 136
Start: 2014-08
Primary completion: 2015-11
Lead sponsor: Sanofi
Conditions: Type 2 Diabetes Mellitus
Interventions: DRUG:LIXISENATIDE AVE0010; DRUG:Sitagliptin; DRUG:Insulin glargine HOE901
Results posted: FALSE
Secondary identifiers: OTHER:U1111-1159-5323

Registered primary outcomes

Change from baseline in postprandial plasma glucose at Day 29 after a standardized breakfast [Day 29 after first intake of investigational product]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0024589	Reduction of postprandial glucose by lixisenatide vs sitagliptin treatment in Japanese patients with type 2 diabetes on background insulin glargine: A randomized phase IV study (NEXTAGE Study). Yamada Y, Diabetes, obesity & metabolism	2017	Randomized trial	PMID 28345162 DOI	cites ClinicalTrials.gov:NCT02200991; registry reference DERIVED:28345162